Skip to main content

Oxford and Qualyst Pen Metabolism Assay Deal

NEW YORK, March 14 (GenomeWeb News) - Oxford Biomedical Research and Qualyst have inked a deal to create a product line of cytochrome P450-inhibition assays to be sold as Accuratet, the companies said today.

 

Under the deal, Qualyst is granting Oxford an exclusive license to manufacture and distribute its CYP activity analysis technology.

 

The first assay to be developed will detect the inhibition of CYP3A4, according to a statement.

 

Financial details were not revealed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.